These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27218790)

  • 61. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
    Awad R; Andrade JCB; Mousa H; Mahmoud F
    Perm J; 2018; 22():17-181. PubMed ID: 30005721
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Angnardo L; Humeda Y; Alexandraki I; Wolfe CM; Cognetta AB
    J Drugs Dermatol; 2021 May; 20(5):552-554. PubMed ID: 33938701
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
    Bayers S; Kapp DL; Beer KR; Slavin B
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.
    Alfieri S; Bergamini C; Granata R; Locati L; Licitra L; Bossi P
    Target Oncol; 2018 Apr; 13(2):253-256. PubMed ID: 29235062
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
    Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
    Viscusi KS; Hanke CW
    J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
    Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S
    Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinoma.
    Sbrana A; Antonuzzo A; Galli L; Biasco E; Musettini G; Paolieri F; Ricci S
    Tumori; 2018 Dec; 104(6):NP2-NP4. PubMed ID: 29895211
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vismodegib for periocular basal cell carcinoma: an international multicentre case series.
    Oliphant H; Laybourne J; Chan K; Haridas A; Edmunds MR; Morris D; Clarke L; Althaus M; Norris P; Cranstoun M; Sullivan TJ; Rajak SN
    Eye (Lond); 2020 Nov; 34(11):2076-2081. PubMed ID: 31996838
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
    Tang JC; Hanke CW; Caro I
    J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery].
    Amici JM; Beylot-Barry M
    Ann Chir Plast Esthet; 2015 Aug; 60(4):321-5. PubMed ID: 25708732
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial.
    Gershoni A; Tiosano A; Ben Ishai M; Barayev E; J Ben Simon G; Yassur I
    Eye (Lond); 2022 Feb; 36(2):407-413. PubMed ID: 33692538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.